Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention

被引:99
作者
Cunha-Oliveira, Teresa [1 ]
Montezinho, Liliana [1 ,2 ]
Mendes, Catarina [1 ,3 ]
Firuzi, Omidreza [4 ]
Saso, Luciano [5 ]
Oliveira, Paulo J. [1 ]
Silva, Filomena S. G. [1 ]
机构
[1] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, UC Biotech Bldg,Biocant Pk, Cantanhede, Portugal
[2] Escola Univ Vasco da Gama, Ctr Invest Vasco da Gama CIVG, Coimbra, Portugal
[3] Polytech Inst Coimbra ESAC, IPC, Coimbra Coll Agr, Coimbra, Portugal
[4] Shiraz Univ Med Sci, Med & Nat Prod Chem Res Ctr, Shiraz, Iran
[5] Sapienza Univ Rome, Dept Physiol & Pharmacol Vittorio Erspamer, Rome, Italy
关键词
TARGETED ANTIOXIDANT MITOQ; MOTOR-NEURON DEGENERATION; TRANSGENIC MOUSE MODEL; ZINC SUPEROXIDE-DISMUTASE; FREE-RADICAL SCAVENGER; VITAMIN-E INTAKE; PERMEABLE PEPTIDE ANTIOXIDANTS; ELEMENT SIGNALING PATHWAY; DOUBLE-BLIND; CEREBROSPINAL-FLUID;
D O I
10.1155/2020/5021694
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2-5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.
引用
收藏
页数:29
相关论文
共 280 条
  • [1] Abe K, 1997, NEUROL RES, V19, P124
  • [2] INDUCTION OF NITROTYROSINE-LIKE IMMUNOREACTIVITY IN THE LOWER MOTOR-NEURON OF AMYOTROPHIC-LATERAL-SCLEROSIS
    ABE, K
    PAN, LH
    WATANABE, M
    KATO, T
    ITOYAMA, Y
    [J]. NEUROSCIENCE LETTERS, 1995, 199 (02) : 152 - 154
  • [3] Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis
    Abe, Koji
    Aoki, Masashi
    Tsuji, Shoji
    Itoyama, Yasuto
    Sobue, Gen
    Togo, Masanori
    Hamada, Chikuma
    Sasaki, Hidenao
    Yabe, Lchiro
    Doi, Shizuki
    Warita, Hitoshi
    Lmai, Takashi
    Ito, Hiroaki
    Fukuchi, Mitsumasa
    Osumi, Etsuko
    Wada, Manabu
    Nakanol, Lmaharu
    Morita, Mitsuya
    Ogata, Katsuhisa
    Maruki, Yuichi
    Ito, Kimiko
    Kano, Osamu
    Yamazaki, IViineo
    Takahashi, Yuji
    Ishiura, Hiroyuki
    Ogino, Micko
    Koike, Ryoko
    Ishida, Chiho
    Uchiyama, Tsuyoshi
    Mizoguchi, Koichi
    Obi, Tomokazu
    Watanabe, Hirohisa
    Atsuta, Naoki
    Aiba, Ikuko
    Taniguchi, Akira
    Sawada, Hideyuki
    Hazama, Takanori
    Fujimura, Harutoshi
    Kusaka, Hirofumi
    Kunieda, Takenobu
    Kikuchi, Hiroshi
    Matsuo, Hidenori
    Ueyama, Hidetsug-U
    Uekawa, Kazutoshi
    Tanaka, Masahiko
    Akimoto, Makoto
    Nakamura, Kazue
    Ueda, Masaki
    Kotani, Kuniko
    Matsui, Hiroshi
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 : 55 - 63
  • [4] Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
    Abe, Koji
    Aoki, Masashi
    Tsuji, Shoji
    Itoyama, Yasuto
    Sobue, Gen
    Togo, Masanori
    Hamada, Chikuma
    Tanaka, Masahiko
    Akimoto, Makoto
    Nakamura, Kazue
    Takahashi, Fumihiro
    Kondo, Kazuoki
    Yoshino, Hiide
    [J]. LANCET NEUROLOGY, 2017, 16 (07) : 505 - 512
  • [5] Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
    Abe, Koji
    Itoyama, Yasuto
    Sobue, Gen
    Tsuji, Shoji
    Aoki, Masashi
    Doyu, Manabu
    Hamada, Chikuma
    Kondo, Kazuoki
    Yoneoka, Takatomo
    Akimoto, Makoto
    Yoshino, Hiide
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2014, 15 (7-8) : 610 - 617
  • [6] Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation
    Abou Ezzi, Samer
    Urushitani, Makoto
    Julien, Jean-Pierre
    [J]. JOURNAL OF NEUROCHEMISTRY, 2007, 102 (01) : 170 - 178
  • [7] Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma
    Abramova, NA
    Cassarino, DS
    Khan, SM
    Painter, TW
    Bennett, JP
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (04) : 494 - 500
  • [8] Relevance of oxidative injury in the pathogenesis of motor neuron diseases
    Agar, J
    Durham, H
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2003, 4 (04): : 232 - 242
  • [9] Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial
    Ahmadi, Mona
    Agah, Elmira
    Nafissi, Shahriar
    Jaafari, Mahmoud Reza
    Harirchian, Mohammad Hossein
    Sarraf, Payam
    Faghihi-Kashani, Sara
    Hosseini, Seyed Jalal
    Ghoreishi, Abdolreza
    Aghamollaii, Vajiheh
    Hosseini, Mostafa
    Tafakhori, Abbas
    [J]. NEUROTHERAPEUTICS, 2018, 15 (02) : 430 - 438
  • [10] The epidemiology of ALS: a conspiracy of genes, environment and time
    Al-Chalabi, Ammar
    Hardiman, Orla
    [J]. NATURE REVIEWS NEUROLOGY, 2013, 9 (11) : 617 - 628